World Hematology 2020

Join us at Edinburgh, UK this March 2-3, 2020 to explore trends in hematology and oncology. For more info, PS: https://rebrand.ly/39g47

Updates in hematology/ oncology

Studies say that anemia is an early and multifactorial complication of multiple myeloma and has been reported to occur in over two thirds of all patients. It also has a negative impact on the quality of patients’ lives and is an independent predictor of poor survival. It is also said that in patients with multiple myeloma, anaemia is usually normocytic and normochromic but can be macrocytic and the anaemia is manifested as a hemoglobin level between 8 and 10 g/dL, while approximately 10% have a value below 8 g/dL. Serum iron levels are usually normal to mildly low; serum ferritin is high and hemosiderin is significant in bone marrow macrophages, consistent with patterns similar to anemia of chronic disease. It is also said that chemotherapy-responsive patients, with or without exogenous erythropoietin administration, often see a normalization of their haemoglobin levels with a resultant improvement in quality of life, despite the impact of patients’ ages and stages of disease.

To discuss more such interesting findings in hematology and oncology, join us at the best hematology, oncology, cancer, leukemia, lymphoma and blood conferences organized. To know more info, PS: Hematology & Oncology congress

 

World Hematology 2020

Scan the code and get the information to join us at the leading and one of the best hematology and oncology conferences held in UK.  PS: https://hematology.cmesociety.com/

Updates in hematology/ oncology

Do you know the most frequent clinical manifestation in multiple myeloma?

The answer to this question goes this way.......

The clinical manifestations in multiple myeloma generally be

• Anemia: 73%
• Osteolytic bone lesions: 67%
• Bone pain: 58%
• Kidney Failure: 48%
• Hypercalcemia: 28%

So, the most frequent manifestation in multiple myeloma is anemia.

To know more interesting updates in hematology and oncology, join us at, PS: World Hematology 2020

World Hematology 2020

Come and Join us in Scotland to witness the gathering of experts in hematology & oncology, this March 2- 3, 2020. More info, PS: https://hematology.cmesociety.com/

#hematology #leukemia #lymphoma #cancer #oncology #Conference #events #meetings #Congress #conferences #AML #Blood #anemia #MDS

World Hematology 2020

Join us at the leading and largest conference on hematology & oncology in Edinburgh, Scotland, this March 2020. Submit your abstracts now & avail early bird offers in registration! For more info, PS: https://hematology.cmesociety.com/abstract-submission

Recent updates in hematology/ oncology

According to new guidelines on venous thromboembolism (VTE) from ASH, pharmacologic prophylaxis is not recommended for patients experiencing major trauma deemed to be at high risk of bleeding.

David R. Anderson, MD, dean of the faculty of medicine at Dalhousie University stated that while pharmacologic prophylaxis reduce the risk of symptomatic pulmonary embolism and deep vein thrombosis by about 10 events per 1,000 patients, the increased risk of major bleeding (24 events per 1,000 patients) outweighs the benefits.

When pharmacologic prophylaxis is used, the panel recommends combined prophylaxis – mechanical prophylaxis in addition to pharmacologic prophylaxis – especially in those patients at high or very high risk of VTE. Evidence shows that the combination approach significantly reduces risk of PE, and strongly suggests it may also reduce risk of symptomatic proximal DVT.

Explore and discuss more recent updates in the field of hematology and oncology with us. Join us in Scotland, this March. Know more information at, PS: World Hematology 2020

Source: https://www.mdedge.com/hematology-oncology/quiz/8776/fast-facts-friday/fast-facts-friday-december-13-2019?channel=59610

Recent updates in hematology/ oncology

Trials show that, children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia reported sustained, clinically meaningful improvement in quality-of-life scores after receiving chimeric antigen receptor T-cell therapy. To know more such updates, join us at: http://tiny.cc/9t8ybz

Recent updates in hematology/ oncology

FDA has approved acalabrutinib for adults with chroniclymphocytic leukemia or small lymphocytic lymphoma as an initial or subsequent therapy. This would mark the second approval under Project Orbis.

FDA used the Real-Time Oncology Review pilot program in its review of the application for acalabrutinib, a process to streamline the submission of data before the completion of the entire drug application “Today, as part of a U.S., Australian and Canadian collaboration known as Project Orbis, the U.S. approved a new treatment option for those living with chronic lymphocytic leukemia or small lymphocytic lymphoma. The FDA’s Project Orbis provides a framework for concurrent submission and review of oncology drug applications among the FDA’s international partners,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, said in a press release.

The FDA based this supplemental approval of acalabrutinib on data from two randomized studies. 

The first trial, which included 535 patients with previously untreated CLL- showed longer PFS among patients assigned acalabrutinib compared with other standard treatments.

The second trial of 310 patients with CLL also showed longer PFS with acalabrutinib vs. other standard treatments.

Common adverse events associated with acalabrutinib included anemia, neutropenia, upper respiratory tract infection, thrombocytopenia headache, diarrhea and musculoskeletal pain.

For more updates on hematology or cancer, please join us at, PS: http://tiny.cc/9t8ybz

Source: Healio hemonc today

Recent trends in hematology/ oncology

FDA approved rivaroxaban for the prevention of venous thromboembolism in hospitalized, acutely ill patients at risk for thromboembolic complications who do not have high bleeding risk. Explore more such facts in: http://tiny.cc/9t8ybz 

World Hematology 2020

FDA grants duvelisib orphan drug designation for the treatment of T-cell lymphoma. Know more oncology at: https://hematology.cmesociety.com/

World Hematology 2020

According to study, four months of induction combination chemotherapy followed by surgical exploration made secondary resection feasible for patients with nonresectable locally advanced pancreatic cancer. Know more oncology at: https://hematology.cmesociety.com/ 

 

Orphan drug status to CT053- Multiple myeloma

The FDA has given orphan drug status to CT053, an investigational chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma.

CT053 (CARsgen Therapeutics) is an autologous, fully human CAR T-cell therapy that targets the B-cell maturation antigen on the surface of cancer cells.

CARsgen’s CT053 is one of the company’s three CAR T-cell products approved for early-stage clinical trials. The others include humanized CD19 CAR-T for B-cell leukemia and lymphoma and GPC3 CAR-T for hepatocellular carcinoma and non-small cell lung cancer.

“FDA orphan designation is an important regulatory milestone in the continued development and commercialization of CT053 anti-BCMA CAR-T cells,” Zonghai Li, MD, PhD, founder, CEO and chief scientific officer of CARsgen said in a press release.

Li added that CT053 showed “outstanding potency” during an exploratory phase 1 clinical study in China, where 19 of 24 patients with relapsed or refractory multiple myeloma had a complete response to therapy. In addition, there were no cases of high-grade (3 or 4) cytokine release syndrome during the study.

The FDA Office of Orphan Products Development grants orphan drug designation to novel drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States. The designation allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials and — upon regulatory approval — 7 years of market exclusivity.

Source: https://www.healio.com/hematology-oncology/myeloma/news/online/%7B05b99e87-898a-4880-8a95-d4b724753854%7D/fda-grants-orphan-drug-status-to-anti-bcma-car-t-cell-therapy-for-multiple-myeloma

Recent Trends in Hematology & Oncology

Trials show that adding pembrolizumab to standard therapy failed to improve clinical outcomes for untreated or relapsed/refractory multiple myeloma. Explore more hemato-oncology at: http://bit.ly/2xaW3zT

Recent Trends in Hematology & Oncology

Trials show that nivolumab in combination with brentuximab vedotin induced high antitumor activity for relapsed or refractory primary mediastinal B-cell lymphoma. Explore more hemonc at: http://bit.ly/2xaW3zT

Recent Trends in Hematology/ Oncology

Research shows that combination of selinexor and dexamethasone induced responses among patients with refractory multiple myeloma. Explore more hemonc at: http://bit.ly/2xaW3zT

   

Recent Trends in Hematology/ Oncology

Research shows that combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells shows activity for relapsed or refractory multiple myeloma. Explore more hemonc at: http://bit.ly/2xaW3zT  

World Hematology 2020

Pulsus Group is glad to announce the 2020 conference in the Hematology and Oncology series, the 12^th World Hematology and Oncology Congress, scheduled to be held on March 2- 3, 2020 at Edinburgh, Scotland around the theme “Unravelling the enigmas in hematology & oncology”. We cordially invite all to join us at the event to explore every single aspect of hematology & oncology. Get to know more details at: World Hematology 2020

FDA approval of daratumumab for Multiple Myeloma

The Food and Drug Administration (FDA) announced their approval of daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.

“Today’s approval of DARZALEX (daratumumab) underscores the significant clinical benefit of this CD38 monoclonal antibody and our efforts to advance treatment paradigms to change the course of the disease,” said Craig Tendler, M.D., Vice President, Clinical Development and Global Medical Affairs, Oncology, Janssen Research & Development, LLC in a press release. “Importantly, this milestone also highlights the efficiency of the FDA’s Real-Time Oncology Review process, ensuring that proven treatment regimens, such as DARZALEX plus lenalidomide and dexamethasone, are made available to patients as soon as possible.”

The decision for approval was made based on results of MAIA, an open-label, randomized (1:1) phase III study comparing dartumumab (16 mg/kg) in combination with lenalidomide and low-dose dexamethasone (DRd) to lenalidomide and low-dose dexamethasone (Rd), in 737 patients.

The trial showed an improvement in progression-free survival (PFS) with DRd compared with Rd. The median PFS had not been reached in the DRd arm and was 31.9 months in the Rd arm (HR 0.56; 95% CI: 0.43, 0.73; p<0.0001). The median time to response was 1.05 months (range: 0.2 to 12.1 months) in the DRd group and 1.05 months (range: 0.3 to 15.3 months) in the Rd group. The median response duration had not been reached in the DRd group and was 34.7 months (95% CI: 30.8, not estimable) in the Rd group.

In the DRd arm, the most frequent (≥20%) adverse reactions were infusion reactions, diarrhea, constipation, nausea, peripheral edema, fatigue, back pain, asthenia, pyrexia, upper respiratory tract infection, bronchitis, pneumonia, decreased appetite, muscle spasms, peripheral sensory neuropathy, dyspnea and cough.

Daratumumab can cause severe and/or serious infusion reactions, including anaphylactic-related ones. Patients should be pre‑medicated with antihistamines, antipyretics and corticosteroids and frequently monitored during the entire infusion. The recommended daratumumab dose is 16 mg/kg actual body weight. 

Get to know more about Hematology & Oncology at World Hematology

 

Source: https://www.cancernetwork.com/multiple-myeloma/fda-approves-daratumumab-combination-multiple-myeloma

Sickle Cell Disease and Voxelotor

According to results of phase 3 study, Voxelotor increased hemoglobin levels and reduced markers of hemolysis among sickle cell disease patients. Although two medications approved by the FDA are available (hydroxyurea and L-glutamine [Endari, Emmaus Life Sciences]), chronic medical complications and early death in persons with sickle cell disease remain a substantial burden. In particular, chronic organ dysfunction has become a leading cause of death in adults with sickle cell disease in the United States.

Voxelotor (GBT440, Global Blood Therapeutics) — a deoxygenated sickle hemoglobin polymerization inhibitor — reversibly binds with hemoglobin to help stabilize the oxygenated hemoglobin state. In a previous phase 1/phase 2 trial, voxelotor demonstrated favorable pharmacokinetics and dose-dependent increases in affinity of hemoglobin and oxygen with low-grade toxic effects.

For the current phase 3, international, multicenter, double-blind HOPE trial,  274 patients with sickle cell disease in a 1:1:1 ratio were assigned to receive once-daily voxelotor at a dose of 1,500 mg (n = 90; median age, 24 years; range, 12-59) or 900 mg (n = 92; median age, 24 years; range, 12-59), or placebo (n = 92; median age, 28 years; range, 12-64).

Most of the patients were black (n = 183) and 159 were female. A majority in each group had homozygous hemoglobin S and had experienced at least two vaso-occlusive crises within the past month. About two-thirds were receiving hydroxyurea.

The percentage of patients who demonstrated an increase in hemoglobin level of more than 1 g/dL at 24 weeks served as the study’s primary endpoint. Change in hemoglobin level from baseline to week 24, markers associated with hemolysis, and the incidence rate of vaso-occlusive crises served as secondary endpoints.

Median follow-up was 42.3 weeks (range, 0.1-73.3) in the 1,500-mg voxelotor group, 38.1 weeks (range, 4-72.4) in the 900-mg voxelotor group, and 37.2 weeks (range, 8.1-72.9) in the placebo arm.

Results of the intention-to-treat analysis showed hemoglobin response at 24 weeks among a significantly higher percentage of patients in the 1,500-mg voxelotor group (51%; 95% CI, 41-61) than the placebo group (7%; 95% CI, 1-12). One-third of patients (33%; 95% CI, 23-42) in the 900-mg voxelotor group responded to the treatment by week 24.

Researchers observed a higher percentage of responses among patients in the 1,500-mg voxelotor group than the placebo group regardless of concurrent hydroxyurea use or anemia severity at baseline.

Adjusted mean change in hemoglobin level from baseline to week 24 in the intention-to-treat analysis was 1.1 g/dL (95% CI, 0.9-1.4) in the 1,500-mg voxelotor group, 0.6 g/dL (95% CI, 0.3-0.8) in the 900-mg dose group and –0.1 g/dL (95% CI, –0.3 to 0.2) in the placebo group.

Fewer patients in the 1,500-mg and 900-mg groups experienced worsening anemia between baseline and 24 weeks than in the placebo group. Additionally, the 1,500-mg group demonstrated significantly greater reductions in indirect bilirubin levels and percentage of reticulocytes than the placebo group.

Grade 3 or higher adverse events occurred among 26% of patients in the 1,500-mg and placebo groups and 23% of patients in the 900-mg group. Investigators determined most adverse events were unrelated to treatment.

The absence of an increased incidence rate of vaso-occlusive crisis with voxelotor despite significant increases in the hemoglobin level suggests that voxelotor raises hemoglobin levels without negatively affecting blood viscosity. Longer-term follow-up is needed to further characterize the effect of voxelotor on the incidence of vaso-occlusive crisis.

The hemoglobin response and reduction in hemolysis observed with an orally administered, once-daily medication with side effects that minimally affect lifestyle may make voxelotor a promising advancement in the management of sickle cell disease if approved by the FDA.

Explore more about hematology at World Hematology 2019 at Rome, Italy, this July. Grab Grab 25% off on your registrations until June 25, 2019. To avail offer, Please do drop us an email at: worldhematology@pulsusglobal.com | worldhematology@pulsusmeet.com

Source: HemOnc Source